N/A
Completed N=11
Blue Light Phototherapy
Grover's Disease · Plaque psoriasis
Source: ClinicalTrials.gov NCT04343586 ↗
Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Mar 2023
Primary outcomePrimary: Efficacy of Blue Light Therapy for Patients With Grover's Disease — 27; 6 lesion count
Summary
This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Efficacy of Blue Light Therapy for Patients With Grover's Disease |
27; 6 | — |
| PRIMARY Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment. |
4.3; 2.3 | — |
Eligibility Criteria
Inclusion Criteria
- Patient's aged 18-89 at time of enrollment
- Previous diagnosis of psoriasis vulgaris or Grover's disease
Exclusion Criteria
- All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
- Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy
- Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease
- topical steroids
- calcineurin inhibitors
- methotrexate
- retinoids
- biologic agents
- Unable to schedule phototherapy sessions
- We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.
Data sourced from ClinicalTrials.gov (NCT04343586). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.